Study guide

2.4 Cytotoxic Chemotherapy & Emetogenic Risk Staging

CDR CSO Board Certified Specialist in Oncology Nutrition Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Introduction & Exam Overview

1.1 About the CDR CSO Exam & Certification Logistics 1.2 How to Navigate and Master This Study Guide

2 Chapter 2: Cancer & Cancer Treatment Modalities

2.1 Cancer Biology, Pathophysiology, & Carcinogenesis 2.2 Staging, Grading, & Surgical Oncology Interventions 2.3 Radiation Therapy Modalities & Radiation Toxicities 2.4 Cytotoxic Chemotherapy & Emetogenic Risk Staging 2.5 Targeted Therapies, Immunotherapies, & CAR-T Cell Therapy 2.6 Hematopoietic Stem Cell Transplantation (HSCT/BMT)

3 Chapter 3: Comprehensive Nutrition Assessment & Malnutrition Staging

3.1 Patient-Generated Subjective Global Assessment (PG-SGA) 3.2 GLIM Criteria for Malnutrition Diagnosis in Oncology 3.3 Cancer Cachexia Staging & Pathophysiology (Fearon Consensus) 3.4 Estimating Energy & Protein Requirements (ESPEN Guidelines) 3.5 Anthropometrics & Body Composition Analysis (DEXA, BIA, CT) 3.6 Biochemical & Inflammatory Marker Interpretation 3.7 Nutrition-Focused Physical Exam (NFPE) in Oncology 3.8 Medical, Oncologic, and Treatment History Review 3.9 Diet and Lifestyle History: Methods and Interpretation 3.10 Cultural, Psychosocial, and Socioeconomic Factors

4 Chapter 4: Nutrition-Impact Side Effect Management & Pharmacotherapy

4.1 Upper GI Symptoms: Anorexia, Early Satiety, Nausea, & Vomiting 4.2 Oral & Mucosal Toxicities: Stomatitis, Mucositis, Dysgeusia, & Xerostomia 4.3 Lower GI Toxicities: Diarrhea, Radiation Enteritis, & Constipation 4.4 Pancreatic Exocrine Insufficiency & PERT Dosing Protocols 4.5 Pharmacotherapy for Anorexia-Cachexia Syndrome & Orexigenics 4.6 Oncologic Emergencies: Tumor Lysis, Hypercalcemia, & Superior Vena Cava Syndrome

5 Chapter 5: Specialized Nutrition Interventions, Disease-Site MNT & Care Coordination

5.1 Enteral Nutrition: Access, Indications, & Formula Selection 5.2 Prophylactic Enteral Tubes in Head & Neck Cancer 5.3 Parenteral Nutrition in Oncology: Indications & Management 5.4 Disease-Site MNT: Head & Neck, Esophageal, & Gastric Cancers 5.5 Disease-Site MNT: Pancreatic, Hepatobiliary, & Colorectal Cancers 5.6 Disease-Site MNT: Hematologic Malignancies & HSCT 5.7 Refeeding Syndrome & Cyclic Nutrition Support Protocols 5.8 Referrals, Care Coordination, and Transitions of Care 5.9 Monitoring, Evaluation, and Nutrition Outcomes

6 Chapter 6: Patient Education, Counseling, & Herbal/Supplement Safety

6.1 Patient Counseling & Motivational Interviewing 6.2 Managing Sensory Alterations & Taste Changes 6.3 Complementary & Alternative Medicine (CAM) in Oncology 6.4 Dietary Supplement & Herbal Safety during Cancer Therapy 6.5 Key Drug-Nutrient Interactions in Oncology

7 Chapter 7: Cancer Survivorship, Palliative Nutrition, & End-of-Life Ethics

7.1 Food Safety & Neutropenic Dietary Evidence 7.2 Cancer Survivorship: AICR/WCRF Guidelines & Lifestyle 7.3 Weight Management & Metabolic Health in Survivorship 7.4 Palliative Nutrition & Goals of Care Alignment 7.5 End-of-Life Ethical Considerations & Bioethics

2.4 Cytotoxic Chemotherapy & Emetogenic Risk Staging

Key Takeaways Explain This Topic AI

Cisplatin is a high-emetogenic (>90% CINV risk) alkylating agent that causes severe nephrotoxicity and renal magnesium/potassium wasting, requiring aggressive pre- and post-infusion 0.9% normal saline hydration supplemented with electrolytes.

Doxorubicin (an antitumor antibiotic) generates free radicals causing cumulative, dose-dependent cardiotoxicity, enforcing a strict lifetime cumulative dose limit of 450–550 mg/m².

Vincristine (a vinca alkaloid) induces autonomic peripheral neuropathy, frequently manifesting as severe constipation, fecal impaction, and paralytic ileus requiring prophylactic bowel regimens.

5-Fluorouracil (5-FU) and its oral prodrug capecitabine commonly induce severe oral mucositis, watery diarrhea, and Palmar-Plantar Erythrodysesthesia (Hand-Foot Syndrome), managed with oral pyridoxine (Vitamin B6) and cryotherapy.

Irinotecan induces both acute cholinergic diarrhea (treated with IV/SC atropine) and delayed severe diarrhea (managed with high-dose loperamide up to 16 mg/day), placing patients at high risk for rapid dehydration.

Last updated: August 2026

2.4 Cytotoxic Chemotherapy & Emetogenic Risk Staging

Systemic cytotoxic chemotherapy utilizes pharmacological agents that interfere with cell division, DNA replication, RNA transcription, and protein synthesis. Because cytotoxic drugs target rapidly dividing cells indiscriminately, they induce predictable toxicities in normal host tissues characterized by high cell turnover rates—specifically the gastrointestinal mucosal epithelium, hair follicles, bone marrow hematopoiesis, and germ cells.

Chemotherapy Classes & Mechanisms of Action

Cytotoxic agents are categorized by their chemical structure and cell-cycle specificity (cell-cycle specific vs. cell-cycle non-specific).

Drug Class Key Representatives Mechanism of Action Primary Clinical Toxicities & CSO Considerations

Alkylating & Platinum Agents Cisplatin, Carboplatin, Cyclophosphamide, Oxaliplatin Cell-cycle non-specific; forms intra- and inter-strand covalent cross-links in DNA, inhibiting replication and transcription. Cisplatin: Highly emetogenic (>90%), severe nephrotoxicity, renal Mg/K wasting, ototoxicity.; Oxaliplatin: Cold-induced peripheral neuropathy, pharyngolaryngeal dysesthesia.; Cyclophosphamide: Hemorrhagic cystitis (requires mesna co-administration and hydration).

Antimetabolites 5-Fluorouracil (5-FU), Capecitabine, Methotrexate, Gemcitabine S-phase specific; structural analogs of purines/pyrimidines or folates that mis-incorporate into DNA/RNA or inhibit thymidylate synthase/DHFR. 5-FU / Capecitabine: Mucositis, severe watery diarrhea, Hand-Foot Syndrome.; Methotrexate: Mucositis, hepatotoxicity, myelosuppression (requires leucovorin rescue).; Gemcitabine: Flu-like syndrome, mild emetogenicity.

Antitumor Antibiotics Doxorubicin, Epirubicin, Bleomycin Cell-cycle non-specific; intercalates between DNA base pairs, inhibits topoisomerase II, generates free radicals. Doxorubicin: Dose-dependent cumulative cardiotoxicity (lifetime limit 450–550 mg/m² ), acute red urine discoloration, severe alopecia, high emetogenicity when combined with cyclophosphamide (AC regimen).

Plant Alkaloids (Vinca Alkaloids, Taxanes, Camptothecins) Vincristine, Paclitaxel, Docetaxel, Irinotecan Vinca/Taxanes: M-phase specific; disrupt microtubule assembly/disassembly.; Irinotecan: S-phase specific; inhibits topoisomerase I. Vincristine: Autonomic neuropathy -> paralytic ileus , severe constipation (minimal myelosuppression).; Paclitaxel: Peripheral neuropathy, fluid retention.; Irinotecan: Acute cholinergic diarrhea (early) & delayed severe diarrhea (late).

Chemotherapy-Induced Nausea & Vomiting (CINV)

CINV is one of the most feared toxicities in oncology. CINV is mediated through central pathways (Chemoreceptor Trigger Zone [CTZ] in the area postrema outside the blood-brain barrier) and peripheral pathways (serotonin [5-HT3] release from enterochromaffin cells in the GI mucosa). +---------------------------------------------------------------------------------------------------------+

  • | EMETOGENIC RISK CATEGORIES |
  • | High Risk (>90% frequency): Cisplatin, High-dose Cyclophosphamide, AC Regimen (Doxorubicin+Cyclo). |
  • | Moderate Risk (30-90%): Carboplatin, Oxaliplatin, Irinotecan, Doxorubicin (monotherapy). |
  • | Low Risk (10-30%): 5-Fluorouracil, Paclitaxel, Docetaxel, Gemcitabine, Etoposide. |
  • | Minimal Risk (<10%): Vincristine, Bleomycin, Rituximab, Trastuzumab. |
  • +---------------------------------------------------------------------------------------------------------+
  • Types of CINV

Acute CINV: Occurs within 0 to 24 hours post-chemotherapy administration; mediated primarily by mucosal serotonin (5-HT3) release.

Delayed CINV: Occurs >24 hours to 5–7 days post-chemotherapy; mediated by Substance P binding to Neurokinin-1 (NK-1) receptors in the central nervous system (prominent with cisplatin and anthracyclines).

Anticipatory CINV: Classical conditioning response occurring prior to chemotherapy administration in patients who experienced poor CINV control during previous cycles.

Modern Antiemetic Prophylaxis

High-emetogenic regimens require a 4-drug combination antiemetic prophylactic regimen:

  • NK-1 Receptor Antagonist (e.g., aprepitant, fosaprepitant)
  • 5-HT3 Receptor Antagonist (e.g., ondansetron, palonosetron)
  • Corticosteroid (dexamethasone)
  • Atypical Antipsychotic (olanzapine)
  • Organ-Specific Toxicities & Targeted MNT Interventions
  • 1. Nephrotoxicity & Electrolyte Wasting (Cisplatin)

Pathophysiology: Cisplatin accumulates in renal proximal convoluted tubule cells, causing acute tubular necrosis, impaired glomerular filtration, and urinary wasting of magnesium, potassium, and calcium.

MNT Interventions:

Pre- and post-chemotherapy IV hydration with 0.9% normal saline (typically 1–2 Liters) containing magnesium sulfate (10–20 mEq) and potassium chloride.

Oral magnesium supplementation (magnesium oxide or magnesium gluconate); monitor for diarrhea.

Monitor BUN, serum creatinine, GFR, and electrolyte panels prior to each cycle.

2. Cardiotoxicity (Doxorubicin / Anthracyclines)

Pathophysiology: Free radical generation damages cardiomyocyte membranes, causing myofibrillar loss and irreversible cardiomyopathy leading to congestive heart failure (CHF).

MNT Interventions:

Enforce lifetime cumulative dose caps ( 450–550 mg/m² for Doxorubicin).

Baseline and periodic left ventricular ejection fraction (LVEF) monitoring via echocardiogram or MUGA scan.

If CHF develops: Sodium-restricted diet (2,000 mg/day) and fluid restriction as clinically indicated.

3. Autonomic Neuropathy & Severe Constipation (Vincristine)

Pathophysiology: Vincristine damages autonomic nerve fibers innervating the gastrointestinal tract, leading to decreased intestinal motility, severe constipation, fecal impaction, and paralytic ileus.

MNT Interventions:

Prophylactic bowel regimen initiated concurrently with Vincristine: Stimulant laxative (senna 1–2 tablets daily) combined with stool softener (docusate sodium).

Osmotic laxatives (polyethylene glycol [PEG 3350] 17g daily).

Ensure adequate fluid intake (2–2.5 L/day) and gradual soluble fiber increase (if oral intake permitted and no ileus present).

4. Dysgeusia, Mucositis & Alopecia

Dysgeusia (Taste Alterations): Common with platinum agents and cyclophosphamide. Patients report a metallic or bitter taste, high urea threshold, or total loss of taste.

MNT: Use plastic utensils instead of stainless steel silverware; consume cold or room-temperature foods; marinate meats in sweet or tart juices; add seasonings (lemon, herbs); trial oral zinc sulfate (220 mg daily) if deficient.

Oral Mucositis (5-FU, Methotrexate, Doxorubicin): Erythema and painful ulcerations.

MNT: Soft, non-irritating diet; cryotherapy (ice chips in mouth during 5-FU bolus infusion to cause local vasoconstriction and reduce drug delivery to oral mucosa); avoid acidic, salty, or coarse foods; daily oral hygiene with non-alcoholic oral rinses.

Hand-Foot Syndrome / Palmar-Plantar Erythrodysesthesia (5-FU, Capecitabine): Erythema, swelling, desquamation, and pain on palms and soles.

MNT: Oral Pyridoxine (Vitamin B6) 50–100 mg daily; topical emollient creams; avoid heat exposure and friction.

Loading diagram... Chemotherapy Agent Specific Toxicities and Clinical Management